

表1 文献一覧表 (続き)

筆頭著者	論文名	雑誌名	発表年
Fagnoni, Philippe	Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.	Support Care Cancer	2006
Gazelle, G Scott	Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.	Radiology	2004
Gil, J M	Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.	Clin Transl Oncol	2006
Goldie, Sue J	Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.	J Natl Cancer Inst	2004
Gordon, Louisa G	A Cost-effectiveness Analysis of Two Rehabilitation Support Services for Women with Breast Cancer.	Breast Cancer Res Treat	2005
Graves, Nicholas	Cost-effectiveness analyses and modelling the lifetime costs and benefits of health-behaviour interventions.	Chronic Illn	2006
Groot, M T	Cost-effectiveness of rituximab (MabThera(R)) in diffuse large B-cell lymphoma in the Netherlands.	Eur J Haematol	2005
Guadagnolo, Beverly A	Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.	J Clin Oncol	2006
Hayashi, Katsumi	Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?	Ann Nucl Med	2005
Hillner, Bruce E	Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.	Cancer	2004

表1 文献一覧表 (続き)

筆頭著者	論文名	雑誌名	発表年
Hornberger, John C	Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.	Cancer	2005
Hornberger, John	Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.	Am J Manag Care	2005
Hur, Chin	The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.	Cancer	2004
Jeruss, Jacqueline S	Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?	Cancer	2006
Karnon, Jonathan	Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.	Pharmacoeconomics	2006
Kent, Michael S	Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model.	Ann Thorac Surg	2005
Konski, Andre	Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.	Int J Radiat Oncol Biol Phys	2006
Konski, Andre	Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.	Cancer	2006

表 1 文献一覧表 (続き)

筆頭著者	論文名	雑誌名	発表年
Konski, Andre	Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).	Int J Radiat Oncol Biol Phys	2005
Konski, Andre	Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.	Int J Radiat Oncol Biol Phys	2004
Kulasingam, Shalini L	Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.	Obstet Gynecol	2006
Lievens, Yolande	Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer.	Int J Radiat Oncol Biol Phys	2005
Lievens, Yolande	CHART in lung cancer: economic evaluation and incentives for implementation.	Radiother Oncol	2005
Limat, Samuel	From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.	Pharmacoeconomics	2004
Limwattananon, S	Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.	J Med Assoc Thai	2006
Lin, O S	Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.	Aliment Pharmacol Ther	2004
Lønning, P E	Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer.	Ann Oncol	2006

表1 文献一覧表 (続き)

筆頭著者	論文名	雑誌名	発表年
Lundkvist, Jonas	Proton therapy of cancer: potential clinical advantages and cost-effectiveness.	Acta Oncol	2005
Lundkvist, Jonas	Economic evaluation of proton radiation therapy in the treatment of breast cancer.	Radiother Oncol	2005
Lundkvist, Jonas	Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma.	Cancer	2005
Manser, Renee	Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.	Lung Cancer	2005
Marchetti, Monia	Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.	Clin Ther	2004
Martikainen, Janne A	Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.	Pharmacoeconomics	2005
Mernagh, P	Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective.	Eur J Endocrinol	2006
Moeremans, K	Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.	Int J Gynecol Cancer	2006
Moeremans, Karen	Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer.	Value Health	2004
Naeim, Arash	Is Adjuvant Therapy for Older Patients with Node (+) Early Breast Cancer cost-effective?*	Breast Cancer Res Treat	2005
Naeim, Arash	Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?	Crit Rev Oncol Hematol	2005

表1 文献一覧表 (続き)

筆頭著者	論文名	雑誌名	発表年
Oestreicher, Nina	Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?	Genet Med	2005
Patel, Derek	Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.	Clin Gastroenterol Hepatol	2005
Penson, David F	The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.	J Urol	2005
Plevritis, Sylvia K	Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.	JAMA	2006
Ramsey, Scott	Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?	Urology	2005
Reed, Shelby D	Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.	J Urol	2004
Reed, Shelby D	Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.	Cancer	2004
Rocchi, A	Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.	Support Care Cancer	2006
Rubenstein, J H	The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma.	Aliment Pharmacol Ther	2005
Stout, Natasha K	Retrospective cost-effectiveness analysis of screening mammography.	J Natl Cancer Inst	2006
Suh, W Warren	Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.	Int J Radiat Oncol Biol Phys	2005

表1 文献一覧表 (続き)

筆頭著者	論文名	雑誌名	発表年
Swigonski, Nancy L	Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma.	Pediatrics	2006
Uyl-de Groot, C A	Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.	Vaccine	2005
van Agthoven, M	A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.	Eur J Cancer	2004
van den Brink, Mandy	Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group.	J Clin Oncol	2004
van den Hout, Wilbert B	Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.	J Natl Cancer Inst	2006
Verma, Shailendra	Capecitabine plus docetaxel combination therapy.	Cancer	2005
Vidal-Trecan, Gwenaëlle M	Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis.	Thyroid	2004
Warren, Emma	Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.	Clin Ther	2004
Zeliadt, Steven B	Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.	Am J Med	2005

表2 效用值一覽

效用值	健康狀態	文獻
0	Late stage prostate cancer	Penson 2005 J Urol
0.01	Chronic myeloid leukemia - acceleraated phase, tx with chemotherapy	Warren 2004 Clin Ther
0.02	Increase in baseline utility when using oral ibandronate for skeletal-related events	De Cock 2005 Clin Ther
0.04	Chronic myeloid leukemia - blast crisis - palliative care	Warren 2004 Clin Ther
0.05	Decrement of gynecomastia	Penson 2005 J Urol
0.09	Time from surgery to discharge for patients with microscopically positive rectal metastases or incomplete local resection metastases at surgery in the PRT + TME group.	van den Brink 2004 J Clin Oncol
0.11	Time from surgery to discharge for patients with microscopically negative rectal metastases at surgery in the PRT + TME group.	van den Brink 2004 J Clin Oncol
0.12	Utility decrement (additive) for moderate diarrhea	Ramsey 2005 Urology
0.12	Decrement of moderate diarrhea	Penson 2005 J Urol
0.14	Glioma disease progression	Martikainen 2005 Pharmacoeconomics
0.15	Therapy of metastatic carcinoma	Uyl-de Groot 2005 Vaccine
0.16	Interferon group at 5 yrs	Dixon 2006 Br J Cancer
0.17	Time from surgery to discharge for patients with microscopically positive rectal metastases or incomplete local resection metastases at surgery in the TME group.	van den Brink 2004 J Clin Oncol
0.18	Utility decrement (additive) for severe diarrhea	Ramsey 2005 Urology
0.18	Decrement of severe diarrhea	Penson 2005 J Urol
0.19	Control group at 5 yrs	Dixon 2006 Br J Cancer

表2 効用値一覧（続き）

効用値	健康状態	文献
0.19	Advanced Breast Cancer- palliative Care	Marchetti 2004 Clin Ther
0.2	Patient with bone metastasis from prostate cancer- pain medication after treatment failure	Konski 2004 Int J Radiat Oncol Biol Phys
0.2	Stroke, severe disability	Cykert 2004 Obstet Gynecol
0.21	Time from surgery to discharge for patients with microscopically negative rectal metastases at surgery in the TME only group.	van den Brink 2004 J Clin Oncol
0.23	Stage III cutaneous melanoma patients, recurrence	Crott 2004 Value Health
0.24	Receiving adjuvant treatment with subsequent relapse	Eggington 2006 Br J Cancer
0.24	Last year of life while on Chemotherapy and other supportive treatments	Konski 2006 Cancer
0.28	Skeletal related events for a month	De Cock 2005 Support Care Cancer
0.28	Patient with skeletal-related event, one month	De Cock 2005 Clin Ther
0.3	Distant recurrence of breast cancer	Oestreicher 2005 Genet Med
0.3	Untreatable hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.3	Metastatic cancer and death	Cykert 2004 Obstet Gynecol
0.31	Utility for breast cancer patient with bone metastases not receiving PA with an SRE	Botteman 2006 Ann Oncol
0.31	Procarbazine, lomustine plus vincristine chemotherapy for glioma	Martikainen 2005 Pharmacoeconomics
0.34	Chronic myeloid leukemia - accelerated phase - palliative care	Warren 2004 Clin Ther
0.38	End of life on either treatment (CHOP or R-CHOP)	Hornberger 2005 Cancer

表2 効用値一覧（続き）

効用値	健康状態	文献
0.39	Baseline	Dooms 2006 Eur Respir J
0.39	Disease progression in patients with diffuse large B-cell lymphoma	Best 2005 Value Health
0.4	Nursing home	Karnon 2006 Pharmacoeconomics
0.4	Gastric cancer stage IV	Dan 2006 Clin Gastroenterol Hepatol
0.4	Utility in month of death	Ramsey 2005 Urology
0.4	Distant metastasis regardless of initial treatment strategy	Suh 2005 Int J Radiat Oncol Biol Phys
0.4	Skeletal related events-free month when receiving IV pamidronate or zoledronic acid	De Cock 2005 Support Care Cancer
0.4	Metastatic bone disease	De Cock 2005 Support Care Cancer
0.4	Utility during terminal state- 1 months before death due to prostate cancer	Penson 2005 J Urol
0.4	Skeletal-related event-free month when receiving IV pamidronate or IV zoledronic acid	De Cock 2005 Clin Ther
0.4	Patients with metastatic bone disease	De Cock 2005 Clin Ther
0.41	Glioma patient after surgery and radiation, age- 45	Martikainen 2005 Pharmacoeconomics
0.42	Chemotherapy	Konski 2006 Cancer
0.42	Skeletal related events-free month when receiving oral ibandronate	De Cock 2005 Support Care Cancer
0.42	Last year of life while receiving chemotherapy and other supportive therapy for prostate cancer	Konski 2005 Int J Radiat Oncol Biol Phys
0.42	Skeletal-related event-free month when receiving oral ibandronate	De Cock 2005 Clin Ther

表2 効用値一覧（続き）

効用値	健康状態	文献
0.43	Chemotherapy alternative, Temozolomide for glioma	Martikainen 2005 Pharmacoeconomics
0.448	Ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol
0.45	Utility 2 months before death	Ramsey 2005 Urology
0.45	Utility during terminal state- 2 months before death due to prostate cancer	Penson 2005 J Urol
0.45	Local and distant recurrence of rectal cancer after total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.45	Advanced Breast Cancer- progression during first line chemotherapy	Marchetti 2004 Clin Ther
0.46	Utility for breast cancer patient with bone metastases receiving PA with an SRE	Botteman 2006 Ann Oncol
0.462	Metastasis	Gil 2006 Clin Transl Oncol
0.48	Survival after disease progression, breast cancer	Verma 2005 Cancer
0.48	Local and distant recurrence of rectal cancer after preoperative radiotherapy (PRT) and total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.48	Detected invasive cervical cancer, stage IV	Goldie 2004 J Natl Cancer Inst
0.49	Progressive stage after recurrence of breast cancer	Hornberger 2005 Am J Manag Care
0.49	Disease progression in breast cancer	Elkin 2004 J Clin Oncol
0.5	Gastric cancer stage III	Dan 2006 Clin Gastroenterol Hepatol
0.5	Thyroidectomy	Mernagh 2006 Eur J Endocrinol
0.5	Life after relapse of breast cancer	Lønning 2006 Ann Oncol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.5	Utility 3 months before death	Ramsey 2005 Urology
0.5	Lung cancer patients treated with CHART or conventional treatment alive with disease	Lievens 2005 Radiother Oncol
0.5	Breast cancer recurrence- chemotherapy treatment, 6 months only	Hornberger 2005 Am J Manag Care
0.5	Utility during terminal state- 3 months before death due to prostate cancer	Penson 2005 J Urol
0.5	cancer	Rubenstein 2005 Aliment Pharmacol Ther
0.5	Post-diagnosis adjuvant chemotherapy for breast cancer	Oestreicher 2005 Genet Med
0.5	Decompensated cirrhosis due to HCV	Patel 2005 Clin Gastroenterol Hepatol
0.5	Patient with bone metastasis from prostate cancer-treatment state	Konski 2004 Int J Radiat Oncol Biol Phys
0.5	Presence of HCC (chronic hepatitis C), all child's classes	Lin 2004 Aliment Pharmacol Ther
0.5	Radio-induced thyroid cancer	Vidal-Trecan 2004 Thyroid
0.51	Metastatic cancer	Moeremans 2006 Int J Gynecol Cancer
0.51	Locoregional relapse	Moeremans 2006 Int J Gynecol Cancer
0.513	Distant disease	Stout 2006 J Natl Cancer Inst
0.52	Stage III cutaneous melanoma patients, during interferon treatment	Crott 2004 Value Health
0.524	Blast phase- all treatments for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.548	Pre-ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.55	Utility 4 months before death	Ramsey 2005 Urology
0.55	Patients with a diagnosis of colorectal cancer during primary therapy	Uyl-de Groot 2005 Vaccine
0.55	Lung cancer patients during treatment with CHART	Lievens 2005 Radiother Oncol
0.55	Utility during terminal state- 4 months before death due to prostate cancer	Penson 2005 J Urol
0.55	Glioma patient who is having their first surgery, age-45	Martikainen 2005 Pharmacoeconomics
0.56	Utility for breast cancer patient with bone metastases not receiving PA without an SRE	Botteman 2006 Ann Oncol
0.56	Positive touch imprint cytology results w/ immediate lymph node dissection with complications	Jeruss 2006 Cancer
0.56	Detected invasive cervical cancer, stage III	Goldie 2004 J Natl Cancer Inst
0.56	Detected invasive cervical cancer, stage II	Goldie 2004 J Natl Cancer Inst
0.58	Distant metastases	Karnon 2006 Pharmacoeconomics
0.58	No touch imprint cytology done w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection with complications	Jeruss 2006 Cancer
0.59	Metastatic cancer	Plevritis 2006 JAMA
0.595	Accelerated-phase or blast crises chronic myeloid leukemia or blast crises	Reed 2004 Cancer
0.6	Chemotherapy	Konski 2006 Int J Radiat Oncol Biol Phys
0.6	Utility 5 months before death	Ramsey 2005 Urology
0.6	Alive with breast cancer + radiotherapy IM-MS	Lievens 2005 Int J Radiat Oncol Biol Phys

表2 効用値一覧 (続き)

効用値	健康状態	文献
0.6	Permanent disability following intracranial bleed	Aujesky 2005 Thromb Haemost
0.6	Utility during terminal state- 5 months before death due to prostate cancer	Penson 2005 J Urol
0.6	Chemoradiotherapy for non-small cell lung carcinoma	Hayashi 2005 Ann Nucl Med
0.6	No complete responders or progression of diffuse large B-cell lymphoma (either CHOP or R-CHOP)	Groot 2005 Eur J Haematol
0.6	Initial treatment with CHOP-R for diffuse large B-cell lymphoma	Groot 2005 Eur J Haematol
0.6	Initial treatment with CHOP for diffuse large B-cell lymphoma	Groot 2005 Eur J Haematol
0.6	Patient with bone metastasis from prostate cancer- during chemotherapy	Konski 2004 Int J Radiat Oncol Biol Phys
0.6	Patient with bone metastasis from prostate cancer undergoing radiotherapy	Konski 2004 Int J Radiat Oncol Biol Phys
0.605	Radiation therapy plus total androgen suppression for prostate cancer (Quality of Well Being)	Konski 2005 Int J Radiat Oncol Biol Phys
0.614	Ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.615	Within 30 days before or after skeletal related events (SRE) in patients with SRE	Reed 2004 J Urol
0.62	Metastatic disease	Limwattananon 2006 J Med Assoc Thai
0.62	Negative touch imprint cytology results w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection with complications	Jeruss 2006 Cancer
0.62	10*3 arm	van den Hout 2006 J Natl Cancer Inst
0.62	After treatment for invasive cervical cancer, stage IV	Goldie 2004 J Natl Cancer Inst
0.624	Secondary cancer, salivary gland	Mernagh 2006 Eur J Endocrinol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.624	Secondary cancer, bone/soft tissue	Mernagh 2006 Eur J Endocrinol
0.624	Secondary cancer (colorectal, bone/soft tissue/salivary)	Mernagh 2006 Eur J Endocrinol
0.628	Within 60 days before or after skeletal related events (SRE) in patients with SRE	Reed 2004 J Urol
0.63	Receiving adjuvant treatment with significant serious adverse events during treatment duration	Eggington 2006 Br J Cancer
0.63	Alive with breast cancer	Lievens 2005 Int J Radiat Oncol Biol Phys
0.637	0-4 weeks post-ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol
0.64	Utility for breast cancer patient with bone metastases receiving PA without an SRE	Botteman 2006 Ann Oncol
0.64	Distant recurrence of rectal cancer after total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.642	Regional cancer	Stout 2006 J Natl Cancer Inst
0.644	Within 90 days before or after skeletal related events (SRE) in patients with SRE	Reed 2004 J Urol
0.644	All patients with multiple myeloma	van Agthoven 2004 Eur J Cancer
0.647	Hormone therapy for prostate cancer (Quality of Well Being)	Konski 2005 Int J Radiat Oncol Biol Phys
0.65	Localized disease	Limwattananon 2006 J Med Assoc Thai
0.65	Gastric cancer Stage I or II	Dan 2006 Clin Gastroenterol Hepatol
0.65	Distant metastasis	Delea 2006 Am J Manag Care
0.65	Utility 6 months before death	Ramsey 2005 Urology

表2 効用値一覧(続き)

効用値	健康状態	文献
0.65	Lung cancer patients during conventional treatment	Lievens 2005 Radiother Oncol
0.65	Utility during terminal state- 6 months before death due to prostate cancer	Penson 2005 J Urol
0.65	Detected invasive cervical cancer, stage I	Goldie 2004 J Natl Cancer Inst
0.65	Child's class B/C (decompensated cirrhosis)	Lin 2004 Aliment Pharmacol Ther
0.652	THT withdrawal - First assessment	Blamey 2005 ANZ J Surg
0.656	Radiation therapy for prostate cancer (Quality of Well Being)	Konski 2005 Int J Radiat Oncol Biol Phys
0.66	No touch imprint cytology test done w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection and no complications	Jeruss 2006 Cancer
0.666	Secondary assessment: THT withdrawals	Blamey 2005 ANZ J Surg
0.67	Disease free hip fracture (1st year)	Delea 2006 Am J Manag Care
0.67	Local recurrence of rectal cancer after total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.67	Local recurrence of rectal cancer after preoperative radiotherapy (PRT) and total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.67	Advanced Breast Cancer- stable or responding to first line chemotherapy	Marchetti 2004 Clin Ther
0.689	Within 30 days before or after skeletal related events (SRE) in patients without SRE	Reed 2004 J Urol
0.69	Terminal phase lung cancer (3-months prior to death from lung cancer)	Manser 2005 Lung Cancer
0.69	Metastatic non-small cell lung cancer (until death)	Manser 2005 Lung Cancer
0.692	Within 60 days before or after skeletal related events (SRE) in patients without SRE	Reed 2004 J Urol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.694	Within 60 days before or after skeletal related events (SRE) in patients without SRE	Reed 2004 J Urol
0.7	Lymphoma	Swigonski 2006 Pediatrics
0.7	High dose chemotherapy after failure of conventional salvage	Guadagnolo 2006 J Clin Oncol
0.7	Adjuvant treatment with no significant serious adverse events	Eggington 2006 Br J Cancer
0.7	Stable stage after recurrence of breast cancer	Hornberger 2005 Am J Manag Care
0.7	Radiotherapy for non-small cell lung carcinoma	Hayashi 2005 Ann Nucl Med
0.7	Hip Fracture as breast cancer treatment-related event	Hillner 2004 Cancer
0.7	Systemic recurrence of breast cancer	Hillner 2004 Cancer
0.7	Distant recurrence of rectal cancer after preoperative radiotherapy (PRT) and total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.7	Time from preoperative radiotherapy (PRT) to surgery for rectal cancer	van den Brink 2004 J Clin Oncol
0.7	Stable disease while on breast cancer therapy	Elkin 2004 J Clin Oncol
0.7	Stroke, moderate disability	Cykert 2004 Obstet Gynecol
0.7	Stroke, mild disability	Cykert 2004 Obstet Gynecol
0.71	Ovarian cancer	Plevritis 2006 JAMA
0.71	Negative touch imprint cytology results w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection and no complications	Jeruss 2006 Cancer
0.71	Positive touch imprint cytology results w/ immediate lymph node dissection and no complications	Jeruss 2006 Cancer

表2 効用値一覧(続き)

効用値	健康状態	文献
0.71	IFN +LDAC therapy for chronic-phase chronic myeloid leukemia	Reed 2004 Cancer
0.7104	Cytogenetic response- Interferon alpha treatment for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.7104	Chronic phase- Interferon alpha treatment for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.712	0-4 weeks post-ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.714	Pre-ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.718	Local recurrence	Gil 2006 Clin Transl Oncol
0.72	Chemotherapy	Limwattananon 2006 J Med Assoc Thai
0.72	STRETCH patients-improvers	Gordon 2005 Breast Cancer Res Treat
0.72	Breast cancer survivors with no further intervention	Gordon 2005 Breast Cancer Res Treat
0.724	Distant recurrence in breast cancer patients	Rocchi 2006 Support Care Cancer
0.729	Hormone therapy	Konski 2006 Int J Radiat Oncol Biol Phys
0.729	Accelerated phase- all treatments for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.73	STRETCH patients-non improvers	Gordon 2005 Breast Cancer Res Treat
0.73	Disease progression-free survival, breast cancer	Verma 2005 Cancer
0.73	Time from surgery to discharge for patients with distant rectal metastases at surgery in the PRT + TME group.	van den Brink 2004 J Clin Oncol
0.739	Hormone therapy for prostate cancer (Health Utilities Index)	Konski 2005 Int J Radiat Oncol Biol Phys

表2 効用値一覧（続き）

効用値	健康状態	文献
0.74	Radioactive iodine treatment (high or low dose) - failure to achieve euthyroidism	Vidal-Trecan 2004 Thyroid
0.741	Disease free with complications	Gil 2006 Clin Transl Oncol
0.749	Patient on radiotherapy (RT) and Androgen deprivation (AD)	Konski 2006 Cancer
0.749	Radiation therapy plus total androgen suppression for prostate cancer (Patient-Oriented Prostate Utility Scale- Rating Scale)	Konski 2005 Int J Radiat Oncol Biol Phys
0.75	No disease	Limwattananon 2006 J Med Assoc Thai
0.75	Treatment for breast cancer + radiotherapy IM-MS	Lievens 2005 Int J Radiat Oncol Biol Phys
0.759	4-8 weeks post-ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol
0.77	Breast cancer in situ	Stout 2006 J Natl Cancer Inst
0.77	Locoregional recurrence (1st year)	Delea 2006 Am J Manag Care
0.77	Contralateral tumor (1st year)	Delea 2006 Am J Manag Care
0.77	Non-intervention patients-improvers	Gordon 2005 Breast Cancer Res Treat
0.77	Non-intervention patients-improvers	Gordon 2005 Breast Cancer Res Treat
0.77	Cancer	Aujesky 2005 Thromb Haemost
0.775	Contralateral breast cancer	Rocchi 2006 Support Care Cancer
0.78	Randomization to preoperative radiotherapy (PRT) or surgery for rectal cancer	van den Brink 2004 J Clin Oncol
0.78	Child's class A (compensated cirrhosis)	Lin 2004 Aliment Pharmacol Ther

表2 効用値一覧 (続き)

効用値	健康状態	文献
0.785	Usual therapy + paclitaxel	Limwattananon 2006 J Med Assoc Thai
0.79	No evidence of disease + radiotherapy IM-MS	Lievens 2005 Int J Radiat Oncol Biol Phys
0.793	Androgen deprivation (AD)	Konski 2006 Cancer
0.793	Hormone therapy for prostate cancer (Patient-Oriented Prostate Utility Scale- Rating Scale)	Konski 2005 Int J Radiat Oncol Biol Phys
0.795	On rhTRH - First assessment	Blamey 2005 ANZ J Surg
0.796	4-8 weeks post-ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.797	Secondary assessment (all patients): On rhTSH	Blamey 2005 ANZ J Surg
0.8	Hip Fracture	Karnon 2006 Pharmacoeconomics
0.8	Persistent disease after high dose chemotherapy	Guadagnolo 2006 J Clin Oncol
0.8	High dose chemotherapy	Guadagnolo 2006 J Clin Oncol
0.8	Treatment for breast cancer	Lievens 2005 Int J Radiat Oncol Biol Phys
0.8	Chemotherapy with major toxicity	Naeim 2005 Breast Cancer Res Treat
0.8	DAART patients (improvers)	Gordon 2005 Breast Cancer Res Treat
0.8	STRETCH treatment participants	Gordon 2005 Breast Cancer Res Treat
0.8	Growth hormone deficiency	Lundkvist 2005 Acta Oncol
0.8	Increased risk of other cardiovascular disease	Lundkvist 2005 Acta Oncol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.8	Regional non-small cell lung cancer (disease free after treatment, until relapse or death from other causes)	Manser 2005 Lung Cancer
0.8	Post-operative health state after surgery for lung cancer (at 6-month time point)	Manser 2005 Lung Cancer
0.8	Other cardiovascular diseases	Lundkvist 2005 Radiother Oncol
0.8	Post-diagnosis: no adjuvant chemotherapy for breast cancer	Oestreicher 2005 Genet Med
0.8	Chemotherapy with major toxicity for node (-) early breast cancer	Naeim 2005 Crit Rev Oncol Hematol
0.8	Post living donor liver transplant for hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.8	Post cadaveric liver transplant for hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.8	Post resection for hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.8	Compensated cirrhosis due to HCV	Patel 2005 Clin Gastroenterol Hepatol
0.8	Time from surgery to discharge for patients with distant rectal metastases at surgery in the TME group.	van den Brink 2004 J Clin Oncol
0.8	Advanced Breast Cancer- progression during second line hormone therapy	Marchetti 2004 Clin Ther
0.8	Advanced Breast Cancer- stable, responding or progression during first line hormone therapy	Marchetti 2004 Clin Ther
0.801	Pre-treatment - First assessment	Blamey 2005 ANZ J Surg
0.802	Secondary assessment (all patients): Pre-treatment	Blamey 2005 ANZ J Surg
0.81	Remission (follow up)	Moeremans 2006 Int J Gynecol Cancer
0.81	Lumpectomy with invasive local recurrence salvaged with conservative surgery and RT	Suh 2005 Int J Radiat Oncol Biol Phys